Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.74
SVA's Cash to Debt is ranked lower than
73% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 49.71 vs. SVA: 1.74 )
Ranked among companies with meaningful Cash to Debt only.
SVA' s Cash to Debt Range Over the Past 10 Years
Min: 0.48  Med: 2.28 Max: N/A
Current: 1.74
Equity to Asset 0.60
SVA's Equity to Asset is ranked lower than
60% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. SVA: 0.60 )
Ranked among companies with meaningful Equity to Asset only.
SVA' s Equity to Asset Range Over the Past 10 Years
Min: 0.41  Med: 0.58 Max: 0.64
Current: 0.6
0.41
0.64
Interest Coverage 2.43
SVA's Interest Coverage is ranked lower than
91% of the 367 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SVA: 2.43 )
Ranked among companies with meaningful Interest Coverage only.
SVA' s Interest Coverage Range Over the Past 10 Years
Min: 0.14  Med: 9.95 Max: 76.38
Current: 2.43
0.14
76.38
F-Score: 5
Z-Score: 3.33
M-Score: -2.52
WACC vs ROIC
2.78%
2.30%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 6.03
SVA's Operating margin (%) is ranked higher than
75% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -73.78 vs. SVA: 6.03 )
Ranked among companies with meaningful Operating margin (%) only.
SVA' s Operating margin (%) Range Over the Past 10 Years
Min: -58.52  Med: 4.81 Max: 48.44
Current: 6.03
-58.52
48.44
Net-margin (%) 3.60
SVA's Net-margin (%) is ranked higher than
73% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -75.29 vs. SVA: 3.60 )
Ranked among companies with meaningful Net-margin (%) only.
SVA' s Net-margin (%) Range Over the Past 10 Years
Min: -59.38  Med: -1.42 Max: 23.7
Current: 3.6
-59.38
23.7
ROE (%) 2.00
SVA's ROE (%) is ranked higher than
77% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -32.24 vs. SVA: 2.00 )
Ranked among companies with meaningful ROE (%) only.
SVA' s ROE (%) Range Over the Past 10 Years
Min: -33.56  Med: -0.67 Max: 33.16
Current: 2
-33.56
33.16
ROA (%) 1.19
SVA's ROA (%) is ranked higher than
78% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. SVA: 1.19 )
Ranked among companies with meaningful ROA (%) only.
SVA' s ROA (%) Range Over the Past 10 Years
Min: -19.03  Med: -0.38 Max: 17.53
Current: 1.19
-19.03
17.53
ROC (Joel Greenblatt) (%) 5.06
SVA's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. SVA: 5.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SVA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -35.83  Med: 5.78 Max: 137.02
Current: 5.06
-35.83
137.02
Revenue Growth (3Y)(%) 2.90
SVA's Revenue Growth (3Y)(%) is ranked lower than
51% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. SVA: 2.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SVA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 25.20 Max: 82.5
Current: 2.9
0
82.5
EBITDA Growth (3Y)(%) 7.00
SVA's EBITDA Growth (3Y)(%) is ranked higher than
64% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. SVA: 7.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SVA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -46.4  Med: 28.30 Max: 224
Current: 7
-46.4
224
» SVA's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-12)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

SVA Guru Trades in Q2 2015

Jim Simons 1,263,200 sh (+6.49%)
» More
Q3 2015

SVA Guru Trades in Q3 2015

Jim Simons 1,292,779 sh (+2.34%)
» More
Q4 2015

SVA Guru Trades in Q4 2015

Jim Simons 1,354,100 sh (+4.74%)
» More
Q1 2016

SVA Guru Trades in Q1 2016

Jim Simons 1,334,600 sh (-1.44%)
» More
» Details

Insider Trades

Latest Guru Trades with SVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:AGEN, NAS:NDRM, NAS:CGEN, NAS:ASND, NAS:MYOK, NAS:BLCM, NAS:VYGR, NAS:TRVN, NAS:CTMX, OTCPK:VNLPY, NAS:TGTX, NAS:TLGT, NAS:CYTK, NAS:OCAT, NAS:ARWR, NAS:OMED, NAS:ESPR, NAS:ACRS, NAS:AMRN, NAS:RVNC » details
Traded in other countries:SVQ.Germany,
Sinovac Biotech Ltd is a biopharmaceutical company engaged in research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases.

Sinovac Biotech Ltd, formerly known as Net-Force System Inc., was incorporated in Antigua and Barbuda on March 1, 1999. The Company is an integrated China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A, hepatitis A and B, seasonal influenza, H5N1 and H1N1 pandemic influenza and mumps, as well as animal rabies vaccine. The Company is engaged in the development, manufacturing and sales of vaccines for infectious diseases. Its product consist of Healive, for the treatment of Hepatitis A; Bilive, for the treatment of Hepatitis A&B; Anflu, for the treatment of Influenza; Panflu Whole Viron Pandemic Influenza Vaccine, for Pandemic Influenza Virus; Split Viron Pandemic Influenza Vaccine, for the treatment of Pandemic Influenza Virus; Panflu.1, for the treatment of Influenza A H1N1 virus; RabEnd, for the treatment of Rabies Virus in animals; Mumps Vaccine, for the treatment of mumps; EV71 Vaccine, Pneumococcal Polysaccharide Vaccine, Varicella Vaccine, for the treatment of varicella-zoster virus, H7N9 Vaccine, for the treatment of H7N9 influenza. The Company has four manufacturing bases located in Haidian and Changping Districts of Beijing, Dalian City of Liaoning Province, and Tangshan City of Hebei Province and also has two upstream production facilities in Haidian District, Beijing. It has built a new production site in in Changping District, Beijing, which comprises a new filing and packaging line that complies with the new PRC GMP standards, EV71 production facilities and a warehouse. The Company relies on its sales force to sell its products directly to CDCs in the private market. As of December 31, 2013, the in-house sales and marketing team consisted of 170 staff members located in 31 provinces throughout China. The Company obtains the raw materials from local and overseas suppliers. It maintains two suppliers for each key raw material, with the exception of hepatitis B antigens for Bilive production. The hepatitis B antigens are sourced from Beijing Temple of Heaven. The Company competes with Kunming Institute of Biological Product, Pukang Biological Co., Ltd., Changchun Institute of Biological Products and Changchun Changsheng Life Sciences Ltd for hepatitis A vaccine. It competes with Hualan Biological Engineering Inc., Changchun Institute of Biological Products, GSK, Aleph Biological Co., Ltd. and Zhejiang Tianyuan for influenza vaccines. The Company is subject to PRC laws and regulations governing the use, manufacture, storage, handling or disposal of hazardous materials and waste products.

Ratios

vs
industry
vs
history
P/E(ttm) 150.75
SVA's P/E(ttm) is ranked lower than
89% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 28.83 vs. SVA: 150.75 )
Ranked among companies with meaningful P/E(ttm) only.
SVA' s P/E(ttm) Range Over the Past 10 Years
Min: 5.44  Med: 22.66 Max: 232.4
Current: 150.75
5.44
232.4
P/B 2.78
SVA's P/B is ranked higher than
58% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 3.34 vs. SVA: 2.78 )
Ranked among companies with meaningful P/B only.
SVA' s P/B Range Over the Past 10 Years
Min: 0.73  Med: 2.35 Max: 11.8
Current: 2.78
0.73
11.8
P/S 4.92
SVA's P/S is ranked higher than
73% of the 799 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. SVA: 4.92 )
Ranked among companies with meaningful P/S only.
SVA' s P/S Range Over the Past 10 Years
Min: 0.97  Med: 4.45 Max: 26.51
Current: 4.92
0.97
26.51
POCF 231.92
SVA's POCF is ranked lower than
97% of the 199 Companies
in the Global Biotechnology industry.

( Industry Median: 22.99 vs. SVA: 231.92 )
Ranked among companies with meaningful POCF only.
SVA' s POCF Range Over the Past 10 Years
Min: 3.73  Med: 17.49 Max: 1135
Current: 231.92
3.73
1135
EV-to-EBIT 61.47
SVA's EV-to-EBIT is ranked lower than
82% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 21.76 vs. SVA: 61.47 )
Ranked among companies with meaningful EV-to-EBIT only.
SVA' s EV-to-EBIT Range Over the Past 10 Years
Min: -484.4  Med: 6.00 Max: 209.6
Current: 61.47
-484.4
209.6
EV-to-EBITDA 29.28
SVA's EV-to-EBITDA is ranked lower than
67% of the 305 Companies
in the Global Biotechnology industry.

( Industry Median: 18.58 vs. SVA: 29.28 )
Ranked among companies with meaningful EV-to-EBITDA only.
SVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1075.2  Med: 6.50 Max: 103.9
Current: 29.28
-1075.2
103.9
Shiller P/E 96.59
SVA's Shiller P/E is ranked lower than
72% of the 54 Companies
in the Global Biotechnology industry.

( Industry Median: 54.39 vs. SVA: 96.59 )
Ranked among companies with meaningful Shiller P/E only.
SVA' s Shiller P/E Range Over the Past 10 Years
Min: 81.33  Med: 126.25 Max: 519
Current: 96.59
81.33
519
Current Ratio 2.20
SVA's Current Ratio is ranked lower than
73% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. SVA: 2.20 )
Ranked among companies with meaningful Current Ratio only.
SVA' s Current Ratio Range Over the Past 10 Years
Min: 1.16  Med: 2.47 Max: 6.15
Current: 2.2
1.16
6.15
Quick Ratio 1.86
SVA's Quick Ratio is ranked lower than
73% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. SVA: 1.86 )
Ranked among companies with meaningful Quick Ratio only.
SVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.22 Max: 5.43
Current: 1.86
0.85
5.43
Days Inventory 365.12
SVA's Days Inventory is ranked lower than
89% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.52 vs. SVA: 365.12 )
Ranked among companies with meaningful Days Inventory only.
SVA' s Days Inventory Range Over the Past 10 Years
Min: 103.07  Med: 188.28 Max: 366.94
Current: 365.12
103.07
366.94
Days Sales Outstanding 211.98
SVA's Days Sales Outstanding is ranked lower than
90% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. SVA: 211.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
SVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 106.38  Med: 176.39 Max: 244.46
Current: 211.98
106.38
244.46
Days Payable 30.36
SVA's Days Payable is ranked lower than
70% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 60.55 vs. SVA: 30.36 )
Ranked among companies with meaningful Days Payable only.
SVA' s Days Payable Range Over the Past 10 Years
Min: 43.56  Med: 82.47 Max: 142.98
Current: 30.36
43.56
142.98

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 7.27
SVA's Price/Net Current Asset Value is ranked lower than
64% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. SVA: 7.27 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SVA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.06  Med: 6.09 Max: 50.13
Current: 7.27
2.06
50.13
Price/Tangible Book 2.78
SVA's Price/Tangible Book is ranked higher than
65% of the 945 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. SVA: 2.78 )
Ranked among companies with meaningful Price/Tangible Book only.
SVA' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.9  Med: 2.48 Max: 14.28
Current: 2.78
0.9
14.28
Price/Median PS Value 1.10
SVA's Price/Median PS Value is ranked lower than
63% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. SVA: 1.10 )
Ranked among companies with meaningful Price/Median PS Value only.
SVA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.28  Med: 1.04 Max: 4.3
Current: 1.1
0.28
4.3
Earnings Yield (Greenblatt) (%) 1.60
SVA's Earnings Yield (Greenblatt) (%) is ranked higher than
80% of the 1100 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. SVA: 1.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SVA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 4.80 Max: 51.4
Current: 1.6
0.5
51.4

More Statistics

Revenue (TTM) (Mil) $69.10
EPS (TTM) $ 0.04
Beta0.13
Short Percentage of Float1.00%
52-Week Range $4.38 - 7.16
Shares Outstanding (Mil)56.91
» More Articles for SVA

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Sinovac Reports Unaudited First Quarter 2016 Financial R... May 26 2016
Sinovac posts 1Q profit May 26 2016
Sinovac posts 1Q profit May 26 2016
Sinovac Reports Unaudited First Quarter 2016 Financial R... May 26 2016
Sinovac Reports Unaudited First Quarter 2016 Financial Results May 26 2016
Q1 2016 Sinovac Biotech Ltd Earnings Release - After Market Close May 26 2016
Sinovac to Host Conference Call to Report First Quarter ... May 20 2016
Sinovac to Host Conference Call to Report First Quarter of 2016 Unaudited Financial Results May 20 2016
Sinovac Files 2015 Annual Report on Form 20-F May 20 2016
3 Underfollowed Infectious Disease Stocks That Deserve More Attention May 03 2016
SINOVAC BIOTECH LTD Financials Apr 29 2016
In China's tougher drug market, minnows open back door for 'Big Pharma' Apr 28 2016
In China's tougher drug market, minnows open back door for 'Big Pharma' Apr 28 2016
Sinovac Biotech Ltd. breached its 50 day moving average in a Bearish Manner : SVA-US : April 27,... Apr 27 2016
Sinovac Files 2015 Annual Report on Form 20-F Apr 26 2016
Sinovac Special Committee Engages Financial and Legal Ad... Apr 14 2016
Sinovac Special Committee Engages Financial and Legal Advisors Apr 14 2016
Sinovac Biotech Ltd. :SVA-US: Earnings Analysis: Q4, 2015 By the Numbers Apr 11 2016
Sinovac Biotech Ltd. :SVA-US: Earnings Analysis: 2015 By the Numbers Apr 11 2016
Sinovac Reports Unaudited Fourth Quarter and Full Year 2... Apr 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)